Vistagen Says Exploratory Phase 2 Repeat Dose Study Of Fasedienol Missed Statistical Significance On Primary Endpoint (p=0.2); Reports Nominal Significance In Very Severe Social Anxiety Subgroup

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 36.17 percent increase over losses of $(0.47) per share

8-K filing — Vistagen Therapeutics, Inc. (VTGN)

Filed: 2026-08-14 AccNo: 0001628280-26-056953 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Vistagen Therapeutics shares are trading higher after SRX Global announced that it has acquired a stake in the company.